<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JNCI Cancer Spectr</journal-id><journal-id journal-id-type="iso-abbrev">JNCI Cancer Spectr</journal-id><journal-id journal-id-type="pmc-domain-id">3695</journal-id><journal-id journal-id-type="pmc-domain">jncicanspec</journal-id><journal-id journal-id-type="publisher-id">jncics</journal-id><journal-title-group><journal-title>JNCI Cancer Spectrum</journal-title></journal-title-group><issn pub-type="epub">2515-5091</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12681321</article-id><article-id pub-id-type="pmcid-ver">PMC12681321.1</article-id><article-id pub-id-type="pmcaid">12681321</article-id><article-id pub-id-type="pmcaiid">12681321</article-id><article-id pub-id-type="pmid">41092066</article-id><article-id pub-id-type="doi">10.1093/jncics/pkaf097</article-id><article-id pub-id-type="publisher-id">pkaf097</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00010</subject></subj-group></article-categories><title-group><article-title>Lifestyle and environmental factors in women carrying <italic toggle="yes">BRCA</italic> pathogenic variants with and without cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0758-8033</contrib-id><name name-style="western"><surname>Fabi</surname><given-names initials="A">Alessandra</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><xref rid="pkaf097-cor1" ref-type="corresp"/><xref rid="pkaf097-FM1" ref-type="author-notes"/><aff>
<institution>Precision Medicine Unit in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6773-3848</contrib-id><name name-style="western"><surname>Franco</surname><given-names initials="A">Antonio</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff>
<institution>Breast Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff><xref rid="pkaf097-FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8950-8561</contrib-id><name name-style="western"><surname>Cortesi</surname><given-names initials="L">Laura</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena</institution>, Modena, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6279-7604</contrib-id><name name-style="western"><surname>Lucci Cordisco</surname><given-names initials="E">Emanuela</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff>
<institution>Medical Genetics, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff><aff>
<institution>Department of Life Sciences and Public Health, Universit&#224; Cattolica del Sacro Cuore</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rossi</surname><given-names initials="A">Alessandro</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff>
<institution>Precision Medicine Unit in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-5048-3593</contrib-id><name name-style="western"><surname>Terribile</surname><given-names initials="DA">Daniela Andreina</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff>
<institution>Breast Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fiorio</surname><given-names initials="E">Elena</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><aff>
<institution>Innovation Biomedicine&#8212;Oncology Area, Department of Engineering for Innovation Medicine, University of Verona and Verona University and Hospital Trust</institution>, Verona, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7445-3366</contrib-id><name name-style="western"><surname>Paris</surname><given-names initials="I">Ida</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff>
<institution>Division of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Terrana</surname><given-names initials="G">Giovanni</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><aff>
<institution>Department of Experimental Medicine, University Sapienza of Rome</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4868-8102</contrib-id><name name-style="western"><surname>Mocini</surname><given-names initials="E">Edoardo</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><aff>
<institution>Department of Theoretical and Applied Sciences, eCampus University</institution>, Novedrate, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-1104-7866</contrib-id><name name-style="western"><surname>Salutari</surname><given-names initials="V">Vanda</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff>
<institution>Division of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4218-6726</contrib-id><name name-style="western"><surname>Pavese</surname><given-names initials="F">Francesco</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><aff>
<institution>Division of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-8017-8050</contrib-id><name name-style="western"><surname>L&#8217;Erario</surname><given-names initials="FF">Francesca Federica</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><aff>
<institution>Medical Genetics, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8220-3420</contrib-id><name name-style="western"><surname>Pasquetti</surname><given-names initials="D">Domizia</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><aff>
<institution>Medical Genetics, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8371-7087</contrib-id><name name-style="western"><surname>Palazzo</surname><given-names initials="A">Antonella</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><aff>
<institution>Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0008-0804-0679</contrib-id><name name-style="western"><surname>Di Guglielmo</surname><given-names initials="E">Enrico</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff>
<institution>Breast Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4840-507X</contrib-id><name name-style="western"><surname>Sanchez</surname><given-names initials="AM">Alejandro Martin</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff>
<institution>Breast Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0223-9635</contrib-id><name name-style="western"><surname>D&#8217;Archi</surname><given-names initials="S">Sabatino</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff>
<institution>Breast Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Giontella</surname><given-names initials="E">Elena</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><aff>
<institution>Innovation Biomedicine&#8212;Oncology Area, Department of Engineering for Innovation Medicine, University of Verona and Verona University and Hospital Trust</institution>, Verona, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8219-5336</contrib-id><name name-style="western"><surname>Di Leone</surname><given-names initials="A">Alba</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff>
<institution>Breast Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cardinali</surname><given-names initials="L">Ludovica</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology">Methodology</role><aff>
<institution>Department of Life Science, Health, and Health Professions, Link Campus University</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saltarelli</surname><given-names initials="R">Rosa</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><aff>Complex Operative Unit <institution>of Oncology, San Giovanni Evangelista Hospital</institution>, Tivoli, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5828-2851</contrib-id><name name-style="western"><surname>Scardina</surname><given-names initials="L">Lorenzo</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><aff>
<institution>Breast Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7265-6429</contrib-id><name name-style="western"><surname>Ferretti</surname><given-names initials="E">Elisabetta</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff>
<institution>Department of Experimental Medicine, University Sapienza of Rome</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3532-0963</contrib-id><name name-style="western"><surname>Carbognin</surname><given-names initials="L">Luisa</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff>
<institution>Precision Medicine Unit in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3826-5237</contrib-id><name name-style="western"><surname>Milella</surname><given-names initials="M">Michele</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Innovation Biomedicine&#8212;Oncology Area, Department of Engineering for Innovation Medicine, University of Verona and Verona University and Hospital Trust</institution>, Verona, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6227-3571</contrib-id><name name-style="western"><surname>Baldari</surname><given-names initials="C">Carlo</given-names></name><degrees>PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><aff>
<institution>Department of Theoretical and Applied Sciences, eCampus University</institution>, Novedrate, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bei</surname><given-names initials="R">Roberto</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><aff>
<institution>Department of Clinical Sciences and Translational Medicine, Tor Vergata University</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carcagni</surname><given-names initials="A">Antonella</given-names></name><degrees>PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</role><aff>
<institution>Epidemiology and Biostatistica, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4209-5285</contrib-id><name name-style="western"><surname>Garganese</surname><given-names initials="G">Giorgia</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision">Supervision</role><aff>
<institution>Breast Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2950-3395</contrib-id><name name-style="western"><surname>Franceschini</surname><given-names initials="G">Gianluca</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Breast Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Genuardi</surname><given-names initials="M">Maurizio</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Medical Genetics, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff><aff>
<institution>Department of Life Sciences and Public Health, Universit&#224; Cattolica del Sacro Cuore</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6085-1195</contrib-id><name name-style="western"><surname>Giannarelli</surname><given-names initials="D">Diana</given-names></name><degrees>PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Epidemiology and Biostatistica, Fondazione Policlinico Universitario A. Gemelli IRCCS</institution>, Rome, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4563-6630</contrib-id><name name-style="western"><surname>Migliaccio</surname><given-names initials="S">Silvia</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Department of Experimental Medicine, University Sapienza of Rome</institution>, Rome, <country country="IT">Italy</country></aff></contrib></contrib-group><author-notes><corresp id="pkaf097-cor1">Corresponding author: Alessandra Fabi, MD, Precision Medicine Unit in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy (<email>alessandra.fabi@policlinicogemelli.it</email>).</corresp><fn id="pkaf097-FM1"><p>Author Contributions: Alessandra Fabi and Antonio Franco contributed equally.</p></fn></author-notes><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-10-14"><day>14</day><month>10</month><year>2025</year></pub-date><volume>9</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">500009</issue-id><elocation-id>pkaf097</elocation-id><history><date date-type="received"><day>10</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>27</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>9</month><year>2025</year></date><date date-type="corrected-typeset"><day>06</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>12</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-12-09 13:25:13.050"><day>09</day><month>12</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pkaf097.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pkaf097.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>In the development of breast cancer and ovarian cancer there may be an influence of lifestyle and environmental factors. This influence could be relevant also in patients with genetic predisposition such as in carriers of germline pathogenic variants in the <italic toggle="yes">BRCA</italic> genes. However, this issue has been addressed in only a few studies so far.</p></sec><sec id="s2"><title>Methods</title><p>In this retrospective, multicenter case-control study, we enrolled participants with a pathogenic variant <italic toggle="yes">BRCA</italic> gene and divided into 2 groups: group 1, patients with breast cancer and/or ovarian cancer, and group 2, subjects without cancer. We compared these groups regarding demographic data as age, body mass index, smoking habits, estroprogestinic use, Mediterranean diet, and physical activity. Multivariable analyses were used to identify predisposing factors. All evaluations were 2-tailed and considered statistically significant if the <italic toggle="yes">P</italic> value&#8201;was less than .05.</p></sec><sec id="s3"><title>Results</title><p>We enrolled 281 participants, 135 (79.4%) with breast cancer, 32 (18.8%) with ovarian cancer, 3 (1.8%) with both, and 111 unaffected (39.5%) women. Independent risk factors associated with cancer were age (<italic toggle="yes">P&#8201;</italic>&lt;&#8201;.0001); body mass index (<italic toggle="yes">P&#8201;</italic>=&#8201;.007); family history (<italic toggle="yes">P&#8201;</italic>=&#8201;.002); occupation (<italic toggle="yes">P&#8201;</italic>=&#8201;.003); smoking habits (<italic toggle="yes">P&#8201;</italic>=&#8201;.012), number of cigarettes smoked (<italic toggle="yes">P&#8201;</italic>=&#8201;.016), and pack-year index (<italic toggle="yes">P&#8201;</italic>=&#8201;.022); and estroprogestinic use (<italic toggle="yes">P&#8201;</italic>=&#8201;.032) and years of estroprogestinic use (<italic toggle="yes">P&#8201;</italic>=&#8201;.029). At multivariate analysis, age (odds ratio [OR] = 1.062; <italic toggle="yes">P&#8201;</italic>&lt;&#8201;.0001), family history (OR = 0.129; <italic toggle="yes">P&#8201;</italic>=&#8201;.001), number of cigarettes smoked (<italic toggle="yes">P&#8201;</italic>=&#8201;.014), and estroprogestinic use (OR = 2.009; <italic toggle="yes">P&#8201;</italic>=&#8201;.025) were statistically significant risk factors associated with cancer development.</p></sec><sec id="s4"><title>Conclusions</title><p>In the development of breast cancer and ovarian cancer, lifestyle and environmental factors seem to play a statistically significant role in the presence of genetic predisposition associated with <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> gene mutations.</p></sec></abstract><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Italian Ministry of Research</institution></institution-wrap></funding-source><award-id>PON ARS01 00693</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>European Union-NRRP&#8211;Mission 4 Component 2 Investment 1.3-NextGenerationEU</institution></institution-wrap></funding-source><award-id>PE 00000003-ON</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Foods-Research and innovation</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Sustainability, Safety and Security-Working ON Food&#8211;CUP</institution></institution-wrap></funding-source><award-id>D93C22000890001-RTDA</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Italian Minister of Health&#8212;Ricerca Corrente 2023</institution></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Breast cancer is the most frequent cancer in women; the lifetime probability of developing invasive breast cancer is estimated to be 12.8%. Ovarian cancer represents the second most common type of gynecologic cancer, with an incidence of 1.5%.<xref rid="pkaf097-B1" ref-type="bibr"><sup>1</sup></xref> Their incidence appears to be higher in Europe and North America and lower in Africa and Southeast Asia in relation to different habits and lifestyle.<xref rid="pkaf097-B2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="pkaf097-B3" ref-type="bibr"><sup>3</sup></xref> A sedentary lifestyle and being overweight seem to play a role in the development of both cancer types. Indeed, it has been described for 2 decades that an increase in body mass index (BMI) of 5 units is correlated with a 12% and 7%-10% increased risk of developing breast cancer and ovarian cancer, respectively.<xref rid="pkaf097-B4" ref-type="bibr"><sup>4-6</sup></xref></p><p>Additionally, genetic factors are also related to the pathogenesis of breast cancer and ovarian cancer. In approximately 20% of patients with triple-negative breast cancer and 20%-25% of women with high-grade serous ovarian cancer, a germline <italic toggle="yes">BRCA</italic> pathogenetic variant gene (<italic toggle="yes">gBRCA</italic> VP) can be found. The <italic toggle="yes">BRCA</italic> genes are involved in homologous recombination repair of double-strand DNA breaks. <italic toggle="yes">BRCA</italic> pathogenetic variant genes disrupt gene function and cause genomic instability, favoring tumor development.<xref rid="pkaf097-B7" ref-type="bibr"><sup>7</sup></xref> Individuals carrying <italic toggle="yes">BRCA1</italic> pathogenetic variant genes have a cumulative risk of developing breast cancer of 72% (95% confidence interval [CI] = 65% to 79%) and 69% in case of <italic toggle="yes">BRCA2</italic> genes (95% CI = 61% to 77%). Regarding ovarian cancer, the risk associated with the presence of a <italic toggle="yes">BRCA</italic> pathogenetic variant gene in the case of <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> is 44% (95% CI = 36% to 53%) and 17% (95% CI = 11% to 25%), respectively. This risk estimate is higher in women who carry the <italic toggle="yes">BRCA</italic> pathogenetic variant gene who have multiple relatives with breast cancer. A similar association with family history was observed for the risk of ovarian cancer.<xref rid="pkaf097-B8" ref-type="bibr"><sup>8-12</sup></xref></p><p>Further, it is known that the exposome plays an important role in the development of cancer.<xref rid="pkaf097-B8" ref-type="bibr"><sup>8</sup></xref> Exposure to many environmental toxic factors, such as bisphenol A and cadmium, has been demonstrated to play a role in the development of cancer acting as an endocrine disruptor and thus, leading to hormonal carcinogenesis.<xref rid="pkaf097-B13" ref-type="bibr"><sup>13</sup></xref> For instance cadmium, a proven carcinogen absorbed into the body from dietary sources, cigarette smoke, and by inhalation in industrial or polluted environments, binds to and activates the estrogen receptor in breast cancer cells promoting cell proliferation through the activation of several different pathways including <italic toggle="yes">PI3K-NRF2</italic>.<xref rid="pkaf097-B13" ref-type="bibr"><sup>13-16</sup></xref> These observations are consistent with the hypothesis that genetic risk related to cancer development might be modified by environmental factors. Previous studies have evaluated factors such as lifestyle, smoking habits, estroprogestinic use, overweight, weight gain, and physical inactivity as potential additional risk elements of breast cancer or ovarian cancer in <italic toggle="yes">BRCA</italic> pathogenetic variant gene carriers with inconclusive results.<xref rid="pkaf097-B17" ref-type="bibr"><sup>17-19</sup></xref> The aim of the STILVARCA study is to evaluate the possible influence of environmental and lifestyle factors in the development of breast cancer or ovarian cancer in <italic toggle="yes">BRCA</italic> pathogenetic variant gene carriers.</p></sec><sec sec-type="methods"><title>Methods</title><p>This is a retrospective, multicenter case-control study (NCT05748353) involving 5 participating centers conducted from January to September 2022. Females with a genetic test diagnostic of a <italic toggle="yes">BRCA</italic> pathogenetic variant gene performed between January 2012 and December 2021 were recruited. The enrolled population was divided into 2 groups: group 1, women with breast cancer and/or ovarian cancer; group 2, unaffected women.</p><p>Inclusion criteria were women aged older than&#8201;18&#8201;years with no upper limit; signature of informed consent; histologic diagnosis of breast cancer (stage I-III with any histotype) or ovarian cancer (stage I-III and any histotype); presence of <italic toggle="yes">BRCA</italic> pathogenetic variant genes or likely pathogenic variants (class V or IV)<xref rid="pkaf097-B20" ref-type="bibr"><sup>20</sup></xref>; no previous prophylactic mastectomy and/or bilateral ovariectomy. Exclusion criteria were absence of variants of <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> class IV or V pathogenic variants, patients who underwent prophylactic breast or ovarian surgery, and patients with stage IV breast cancer or ovarian cancer.</p><p>Data collection was prospectively updated in a unique database. This study was conducted in accordance with the ethical standards as laid down in the Declaration of Helsinki and was approved by the central ethics committee of Fondazione Policlinico Agostino Gemelli, Rome (number: RS 4472).<xref rid="pkaf097-B21" ref-type="bibr"><sup>21</sup></xref></p><sec><title>Data collection</title><p>Data collected were acquired before the diagnosis of cancer for group 1 and at enrollment for group 2 and are shown in <xref rid="sup1" ref-type="supplementary-material">Table S1</xref>. The difference in environmental exposure assessment is intended to prevent the change in the patient&#8217;s lifestyle and habits following the diagnosis of malignancy from invalidating the study results. The following datasets were collected:</p><list list-type="order"><list-item><p>Demographic: age (at cancer diagnosis for group 1 and at enrollment for group 2); BMI; family history (presence of other first grade family members with breast cancer or ovarian cancer); ethnic group; gene involved (<italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic>); occupation (divided into employed, educative professions and students, health-care professions, unemployed or retired, and other)</p></list-item><list-item><p>Smoking habits divided into no smoker or ex-smoker, smoker of less than 10 cigarettes per day, smoker of 10-20 cigarettes per day, and smoker of more than 20 cigarettes per day; years of smoking; pack-year index</p></list-item><list-item><p>Estroprogestin exposure including use and duration of estroprogestinic use</p></list-item><list-item><p>Cancer description: site of cancer (breast cancer or ovarian cancer); surgery (demolitive or conservative for breast cancer and demolitive for ovarian cancer)</p></list-item><list-item><p>Histotype</p></list-item><list-item><p>Biological subtypes for breast cancer (luminal tumor [estrogen receptor and/or progesterone receptor positivity, HER2 negative [0, 1+, 2+; with silver in situ hybridization or fluorescence in situ hybridization not amplified]; triple-negative [estrogen and progesterone receptors negative, HER2 negative]; HER2-enriched estrogen receptor and progesterone receptor negative, HER2 2+ silver in situ hybridization/fluorescence in situ hybridization amplified or HER2 3+])</p></list-item><list-item><p>Oncological treatments (neoadjuvant chemotherapy [NACT] or adjuvant chemotherapy)</p></list-item><list-item><p>Nutritional evaluation with adherence to Mediterranean diet (reported by PREDIMED questionnaire)&#160;(<xref rid="sup1" ref-type="supplementary-material">Figure S1A</xref>)<xref rid="pkaf097-B22" ref-type="bibr"><sup>22</sup></xref></p></list-item><list-item><p>Physical activity evaluated with the International Physical Activity Questionnaire short form (IPAQ-SF) (<xref rid="sup1" ref-type="supplementary-material">Figure S1B</xref>)</p></list-item></list><p>The PREDIMED questionnaire, a validated 17-item tool, assesses adherence to the Mediterranean diet. Scores are categorized as follows: poor adherence (&#8804;7), moderate adherence,<xref rid="pkaf097-B8" ref-type="bibr"><sup>8-10</sup></xref> and high adherence (&#8805;11). The IPAQ-SF questionnaire measures the type and amount (days per week and minutes per day) of physical activity performed during the week considering 3 types of activities: vigorous, moderate, and walking. Total metabolic activity equivalents (METs) were calculated as the sum of walking, moderate, and vigorous MET scores. Physical activity was classified as moderate when there were&#8201;at least 3&#8201;days of vigorous intensity activity lasting at least 20&#8201;minutes per day; or at least 5&#8201;days of moderate intensity activity and/or walking for at least 30&#8201;minutes per day; or at least 5&#8201;days of any combination of walking, moderate intensity, or vigorous intensity activities with a total of at least 600 MET minutes per week. The high category comprised vigorous intensity activity on at least&#8201;3&#8201;days at a total of at least&#8201;1500 MET minutes per week; or&#8201;7&#8201;or more days of any combination of walking, moderate intensity, or vigorous intensity activities at a total of&#8201;3000 or more MET minutes per week. Individuals not meeting the criteria for moderate or vigorous categories were classified as low physical activity. Questionnaires were submitted during the outpatient visit.</p></sec><sec><title>Statistical analyses</title><p>Continuous variables were described by mean (SD) (median and interquartile range) and compared with Student <italic toggle="yes">t</italic> test. Categorical variables have been described by absolute number and percentage, and associations were assessed with the &#967;<sup>2</sup> test. Initially, we evaluated differences of these factors between group 1 and group 2. Then, we tested these aspects on the different types of neoplasia by identifying a group of patients with breast cancer, a group of patients with ovarian cancer, and a group of unaffected patients. Finally, we performed univariate and multivariable analyses, using binary logistic regression, aiming to identify predisposing factors for cancer development. Odds ratios (ORs) were reported along with their 95% confidence intervals. All statistical evaluations were 2-tailed and considered significant if the <italic toggle="yes">P-</italic>value was less than .05 (<italic toggle="yes">P&#8201;</italic>&lt;&#8201;.05). Statistical analysis was performed using SPSS ver. 26.0 (Statistical Package of Social Sciences).</p></sec></sec><sec sec-type="results"><title>Results</title><p>We enrolled 281 patients (<xref rid="pkaf097-T1" ref-type="table">Table&#160;1</xref>). Of these patients, 170 (60.5%) had a previous cancer: 135 (79.4%) breast cancer, 32 (18.8%) ovarian cancer, and 3 (1.8%) both breast cancer and ovarian cancer. The remaining 111 (39.5%) patients had no history of cancer.</p><table-wrap position="float" id="pkaf097-T1" orientation="portrait"><label>Table 1.</label><caption><p>Characteristics of patients with cancer diagnosis (group 1)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="char" char="(" span="1"/></colgroup><thead><tr><th rowspan="2" colspan="1">Breast cancer</th><th align="center" rowspan="1" colspan="1">Total patients, No. (%)</th></tr><tr><th align="center" rowspan="1" colspan="1">(<italic toggle="yes">n</italic> = 135)</th></tr></thead><tbody><tr><td colspan="2" rowspan="1">Biological subtype</td></tr><tr><td rowspan="1" colspan="1">&#8195;Triple negative</td><td rowspan="1" colspan="1">61 (45.2)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Luminal B</td><td rowspan="1" colspan="1">44 (32.6)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Luminal A</td><td rowspan="1" colspan="1">15 (11.1)</td></tr><tr><td rowspan="1" colspan="1">&#8195;HER2 enriched<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td><td rowspan="1" colspan="1">15 (11.1)</td></tr><tr><td colspan="2" rowspan="1">Histotype</td></tr><tr><td rowspan="1" colspan="1">&#8195;Invasive ductal carcinoma</td><td rowspan="1" colspan="1">117 (86.7)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Invasive lobular carcinoma</td><td rowspan="1" colspan="1">11 (8.1)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Invasive carcinoma no special type</td><td rowspan="1" colspan="1">7 (5.2)</td></tr><tr><td colspan="2" rowspan="1">Systemic treatment</td></tr><tr><td rowspan="1" colspan="1">&#8195;Neoadjuvant CT</td><td rowspan="1" colspan="1">54 (40.0)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Adjuvant CT</td><td rowspan="1" colspan="1">42 (31.1)</td></tr><tr><td rowspan="1" colspan="1">&#8195;No CT</td><td rowspan="1" colspan="1">39 (28.9)</td></tr><tr><td colspan="2" rowspan="1">Surgery</td></tr><tr><td rowspan="1" colspan="1">&#8195;Conservative<xref rid="tblfn3" ref-type="table-fn"><sup>b</sup></xref></td><td rowspan="1" colspan="1">43 (31.9)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Demolitive<xref rid="tblfn4" ref-type="table-fn"><sup>c</sup></xref></td><td rowspan="1" colspan="1">92 (68.1)</td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="char" char="(" span="1"/></colgroup><thead><tr><th rowspan="2" colspan="1">Ovarian cancer</th><th align="center" rowspan="1" colspan="1">Total patients, No. (%)</th></tr><tr><th align="center" rowspan="1" colspan="1">(<italic toggle="yes">n</italic> = 32)</th></tr></thead><tbody><tr><td colspan="2" rowspan="1">Histotype</td></tr><tr><td rowspan="1" colspan="1">&#8195;High-grade serous carcinoma</td><td rowspan="1" colspan="1">28 (87.5)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Endometrioid ovarian carcinoma</td><td rowspan="1" colspan="1">2 (6.25)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Clear cell ovarian carcinoma</td><td rowspan="1" colspan="1">2 (6.25)</td></tr><tr><td colspan="2" rowspan="1">Systemic treatment</td></tr><tr><td rowspan="1" colspan="1">&#8195;Adjuvant CT</td><td rowspan="1" colspan="1">24 (75.0)</td></tr><tr><td rowspan="1" colspan="1">&#8195;No CT</td><td rowspan="1" colspan="1">8 (25.0)</td></tr><tr><td colspan="2" rowspan="1">Surgery</td></tr><tr><td rowspan="1" colspan="1">&#8195;Radical hysterectomy with annessiectomy, lymphadenectomy and omentectomy, and selective peritonectomy</td><td rowspan="1" colspan="1">18 (56.3)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Radical hysterectomy with annessiectomy</td><td rowspan="1" colspan="1">8 (25.0)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Radical hysterectomy with annessiectomy and lymphadenectomy/omentectomy</td><td rowspan="1" colspan="1">6 (18.7)</td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="char" char="(" span="1"/></colgroup><thead><tr><th rowspan="2" colspan="1">Breast and ovarian cancer</th><th align="center" rowspan="1" colspan="1">Total patients, No. (%)</th></tr><tr><th align="center" rowspan="1" colspan="1">(<italic toggle="yes">n</italic> = 3)</th></tr></thead><tbody><tr><td colspan="2" rowspan="1">Histotype</td></tr><tr><td rowspan="1" colspan="1">&#8195;High-grade serous carcinoma plus invasive ductal carcinoma</td><td rowspan="1" colspan="1">3 (100.0)</td></tr><tr><td colspan="2" rowspan="1">Treatment</td></tr><tr><td rowspan="1" colspan="1">&#8195;Neoadjuvant CT</td><td rowspan="1" colspan="1">3 (100.0)</td></tr><tr><td colspan="2" rowspan="1">Surgery</td></tr><tr><td rowspan="1" colspan="1">&#8195;Demolitive breast surgery<xref rid="tblfn4" ref-type="table-fn"><sup>c</sup></xref> plus radical hysterectomy with annessiectomy, lymphadenectomy/omentectomy, and selective peritonectomy</td><td rowspan="1" colspan="1">3 (100.0)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Abbreviation: CT = chemotherapy.</p></fn><fn id="tblfn2"><label>a</label><p>HER2 2+ silver in situ hybridization&#160;and&#160;fluorescence in situ hybridization amplified, HER2 3+.</p></fn><fn id="tblfn3"><label>b</label><p>Quadrantectomy or monolateral conservative or demolitive mastectomy.</p></fn><fn id="tblfn4"><label>c</label><p>Bilateral conservative or radical mastectomies.</p></fn></table-wrap-foot></table-wrap><p>The 2 most common breast biological subtypes were triple negative (61 [45.2%] patients) and luminal B (44 [32.6%] patients). Among the patients, 86.7% (117 of 135) showed ductal invasive carcinoma. Most patients received chemotherapeutic treatment (54 [40%] NACT; 42 [31.1%] adjuvant chemotherapy). Only 39 (28.9%) breast cancer patients received only antihormonal treatment. Finally, complete ablative surgery (mastectomy of both breasts) was performed in 92 (68.1%) patients. Conservative surgery was chosen when patients had not yet been diagnosed with a <italic toggle="yes">BRCA</italic> pathogenetic variant gene at the time of surgery or when there were contraindications to bilateral mastectomy.</p><p>The most common histotype in ovarian cancer was high-grade serous ovarian carcinoma. This was observed in 28 (87.6%) patients. Among all patients, 18 (56.3%) underwent radical surgery (radical hysterectomy plus adnexectomy, lymphadenectomy and omentectomy, and selective peritonectomy). Most patients underwent adjuvant chemotherapy (24 [75%]).</p><p>Finally, 3 patients showed synchronous breast cancer and ovarian cancer. All showed high-grade serous ovarian carcinoma and breast invasive ductal carcinoma and underwent NACT followed by bilateral mastectomy.</p><p>Overall, the mean age was 42.8 (12.1) years (<xref rid="pkaf097-T2" ref-type="table">Table&#160;2</xref>). The mean age was higher in group 1 (44.7 [10.0]&#8201;years in group 1 and 37.3 [12.9]&#8201;years in group 2; <italic toggle="yes">P&#8201;</italic>&lt;&#8201;.0001]). BMI was statistically significant higher in group 1 (24.5 [4.4] kg/m<sup>2</sup>) as compared with group 2 (23.0 [4.1] kg/m<sup>2</sup>; <italic toggle="yes">P&#8201;</italic>=&#8201;.006). A total of 251 (89.3%) patients had a positive family history. Group 2 had a higher incidence of positive family history (97.3% vs 86.5%; <italic toggle="yes">P&#8201;</italic>&lt;&#8201;.001). Group 1 presented a higher fraction of patients with smoking habits (38.8% vs 24.3%; <italic toggle="yes">P&#8201;</italic>=&#8201;.008), as well as a higher number of cigarettes smoked. Group 1 presented a higher percentage of smokers of more than 10 cigarettes per day than group 2 (23.5% vs 8.1%; <italic toggle="yes">P&#8201;</italic>=&#8201;.008). This is associated with a statistically higher number of index pack-years for patients with cancer (4.2 [8.1] vs 2.0 [5.8]; <italic toggle="yes">P&#8201;</italic>=&#8201;.001). Finally, the last difference was in estroprogestinic use. A significantly higher and longer (for more years) use of estroprogestinic use was observed in group 1: 33.5% in group 1 and 21.6% in group 2 (<italic toggle="yes">P&#8201;</italic>=&#8201;.021).</p><table-wrap position="float" id="pkaf097-T2" orientation="portrait"><label>Table 2.</label><caption><p>Description and comparison of group 1 and group 2 patient characteristics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="2" colspan="1">Characteristics</th><th rowspan="1" colspan="1">Total patients, No. (%)</th><th rowspan="1" colspan="1">Group 1 patients with breast cancer and/or ovarian cancer, No. (%)</th><th rowspan="1" colspan="1">Group 2 patients without breast cancer and ovarian cancer, No. (%)</th><th rowspan="2" align="center" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th rowspan="1" colspan="1">(<italic toggle="yes">n</italic> = 281)</th><th rowspan="1" colspan="1">(<italic toggle="yes">n</italic> = 170 [60.5%])</th><th rowspan="1" colspan="1">(<italic toggle="yes">n</italic> = 111 [39.5%])</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic toggle="yes">BRCA</italic> pathogenic variants</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="3" colspan="1">.804</td></tr><tr><td rowspan="1" colspan="1">&#8195;<italic toggle="yes">BRCA</italic> 1</td><td rowspan="1" colspan="1">168 (59.8)</td><td rowspan="1" colspan="1">103 (60.6)</td><td rowspan="1" colspan="1">65 (58.6)</td></tr><tr><td rowspan="1" colspan="1">&#8195;<italic toggle="yes">BRCA</italic> 2</td><td rowspan="1" colspan="1">113 (40.2)</td><td rowspan="1" colspan="1">67 (39.4)</td><td rowspan="1" colspan="1">46 (41.4)</td></tr><tr><td rowspan="1" colspan="1">Age, mean (SD), y</td><td rowspan="1" colspan="1">42.8&#8201;(12.1)</td><td rowspan="1" colspan="1">44.7&#8201;(10.0)</td><td rowspan="1" colspan="1">37.3&#8201;(12.9)</td><td rowspan="1" colspan="1">
<bold>.001</bold>
</td></tr><tr><td rowspan="1" colspan="1">Body mass index, mean (SD), kg/m<sup>2</sup></td><td rowspan="1" colspan="1">23.9&#8201;(4.3)</td><td rowspan="1" colspan="1">24.5 (4.4)</td><td rowspan="1" colspan="1">23.0 (4.1)</td><td rowspan="1" colspan="1">
<bold>.006</bold>
</td></tr><tr><td rowspan="1" colspan="1">Family history</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="3" colspan="1">
<bold>&lt;.001</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td rowspan="1" colspan="1">251 (89.3)</td><td rowspan="1" colspan="1">143 (84.1)</td><td rowspan="1" colspan="1">108 (97.3)</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td rowspan="1" colspan="1">30 (10.7)</td><td rowspan="1" colspan="1">27 (15.9)</td><td rowspan="1" colspan="1">3 (2.7)</td></tr><tr><td rowspan="1" colspan="1">Occupation</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="6" colspan="1">
<bold>.001</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;Employed</td><td rowspan="1" colspan="1">132 (47.0)</td><td rowspan="1" colspan="1">85 (50.0)</td><td rowspan="1" colspan="1">47 (42.3)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Educative profession</td><td rowspan="1" colspan="1">26 (9.3)</td><td rowspan="1" colspan="1">15 (8.8)</td><td rowspan="1" colspan="1">11 (9.9)</td></tr><tr><td rowspan="1" colspan="1">Health-care profession</td><td rowspan="1" colspan="1">45 (16.0)</td><td rowspan="1" colspan="1">27 (15.9)</td><td rowspan="1" colspan="1">18 (16.2)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Unemployed or retired</td><td rowspan="1" colspan="1">46 (16.3)</td><td rowspan="1" colspan="1">34 (20.0)</td><td rowspan="1" colspan="1">12 (10.8)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Other</td><td rowspan="1" colspan="1">32 (11.4)</td><td rowspan="1" colspan="1">9 (5.3)</td><td rowspan="1" colspan="1">23 (20.7)</td></tr><tr><td rowspan="1" colspan="1">Smoking habits</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="3" colspan="1">
<bold>.008</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td rowspan="1" colspan="1">93 (33.1)</td><td rowspan="1" colspan="1">66 (38.8)</td><td rowspan="1" colspan="1">27 (24.3)</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td rowspan="1" colspan="1">188 (66.9)</td><td rowspan="1" colspan="1">104 (61.2)</td><td rowspan="1" colspan="1">84 (75.7)</td></tr><tr><td rowspan="1" colspan="1">No. cigarettes per day</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="5" colspan="1">
<bold>.008</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;Non&#160;smoker</td><td rowspan="1" colspan="1">188 (66.9)</td><td rowspan="1" colspan="1">104 (61.2)</td><td rowspan="1" colspan="1">84 (75.7)</td></tr><tr><td rowspan="1" colspan="1">&#8195;&lt;10</td><td rowspan="1" colspan="1">44 (15.6)</td><td rowspan="1" colspan="1">26 (15.3)</td><td rowspan="1" colspan="1">18 (16.2)</td></tr><tr><td rowspan="1" colspan="1">&#8195;10-20</td><td rowspan="1" colspan="1">35 (12.5)</td><td rowspan="1" colspan="1">28 (16.5)</td><td rowspan="1" colspan="1">7 (6.3)</td></tr><tr><td rowspan="1" colspan="1">&#8195;&gt;20</td><td rowspan="1" colspan="1">14 (5.0)</td><td rowspan="1" colspan="1">12 (7.0)</td><td rowspan="1" colspan="1">2 (1.8)</td></tr><tr><td rowspan="1" colspan="1">Index pack-years, mean (SD)</td><td rowspan="1" colspan="1">3.3&#8201;(7.3)</td><td rowspan="1" colspan="1">4.2&#8201;(8.1)</td><td rowspan="1" colspan="1">2.0&#8201;(5.8)</td><td rowspan="1" colspan="1">
<bold>.001</bold>
</td></tr><tr><td rowspan="1" colspan="1">Estroprogestinic use</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="3" colspan="1">
<bold>.021</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td rowspan="1" colspan="1">81 (28.8)</td><td rowspan="1" colspan="1">57 (33.5)</td><td rowspan="1" colspan="1">24 (21.6)</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td rowspan="1" colspan="1">200 (71.2)</td><td rowspan="1" colspan="1">113 (66.5)</td><td rowspan="1" colspan="1">87 (78.4)</td></tr><tr><td rowspan="1" colspan="1">Years of estroprogestinic use, mean (SD)</td><td rowspan="1" colspan="1">1.8&#8201;(4.6)</td><td rowspan="1" colspan="1">2.4&#8201;(5.1)</td><td rowspan="1" colspan="1">1.1&#8201;(3.4)</td><td rowspan="1" colspan="1">
<bold>&lt;.0001</bold>
</td></tr><tr><td rowspan="1" colspan="1">Mediterranean diet</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="4" colspan="1">.201</td></tr><tr><td rowspan="1" colspan="1">&#8195;Low adherence</td><td rowspan="1" colspan="1">28 (10.0)</td><td rowspan="1" colspan="1">20 (11.8)</td><td rowspan="1" colspan="1">8 (7.2)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Moderate adherence</td><td rowspan="1" colspan="1">113 (40.2)</td><td rowspan="1" colspan="1">62 (36.5)</td><td rowspan="1" colspan="1">51 (45.9)</td></tr><tr><td rowspan="1" colspan="1">&#8195;High adherence</td><td rowspan="1" colspan="1">140 (49.8)</td><td rowspan="1" colspan="1">88 (51.8)</td><td rowspan="1" colspan="1">52 (46.8)</td></tr><tr><td rowspan="1" colspan="1">Physical activity</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="4" colspan="1">.509</td></tr><tr><td rowspan="1" colspan="1">&#8195;Inactive</td><td rowspan="1" colspan="1">86 (30.6)</td><td rowspan="1" colspan="1">51 (30.0)</td><td rowspan="1" colspan="1">35 (31.5)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Moderate active</td><td rowspan="1" colspan="1">116 (41.3)</td><td rowspan="1" colspan="1">67 (39.4)</td><td rowspan="1" colspan="1">49 (44.1)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Active</td><td rowspan="1" colspan="1">79 (28.1)</td><td rowspan="1" colspan="1">52 (30.6)</td><td rowspan="1" colspan="1">27 (24.3)</td></tr></tbody></table></table-wrap><p>Considering the factors associated with individual disease (<xref rid="sup1" ref-type="supplementary-material">Table S2</xref>), the factors that maintain statistical significance among the 3 groups are age (higher among ovarian cancer patients; <italic toggle="yes">P&#8201;</italic>&lt;&#8201;.0001), BMI (higher in ovarian cancer patients; <italic toggle="yes">P&#8201;</italic>=&#8201;.010), family history (especially in ovarian cancer patients; <italic toggle="yes">P&#8201;</italic>=&#8201;.001), and smoking habits, which is confirmed to be more present in patients with neoplasm (<italic toggle="yes">P&#8201;</italic>=&#8201;.039). The association with estroprogestinic intake loses significance (<italic toggle="yes">P&#8201;</italic>=&#8201;.085).</p><p>In the&#160;univariate analysis (<xref rid="pkaf097-T3" ref-type="table">Table&#160;3</xref>), independent risk factors associated with cancer were age (<italic toggle="yes">P&#8201;</italic>&lt;&#8201;.0001); BMI (<italic toggle="yes">P&#8201;</italic>=&#8201;.007); family history (<italic toggle="yes">P&#8201;</italic>=&#8201;.002); occupation (<italic toggle="yes">P&#8201;</italic>=&#8201;.003); smoking habits (<italic toggle="yes">P&#8201;</italic>=&#8201;.012), number of cigarettes smoked (<italic toggle="yes">P&#8201;</italic>=&#8201;.016), and pack-year index (<italic toggle="yes">P&#8201;</italic>=&#8201;.022); and estroprogestinic use (<italic toggle="yes">P&#8201;</italic>=&#8201;.032) and years of estroprogestinic intake (<italic toggle="yes">P&#8201;</italic>=&#8201;.029). In&#160;a multivariable analysis, age (OR = 1.062; <italic toggle="yes">P&#8201;</italic>&lt;&#8201;.0001), family history (OR = 0.129; <italic toggle="yes">P&#8201;</italic>=&#8201;.001), number of cigarettes smoked (<italic toggle="yes">P&#8201;</italic>=&#8201;.014), and estroprogestinic use (OR = 2.009; <italic toggle="yes">P&#8201;</italic>=&#8201;.025) were negative predictive factors associated with cancer development.</p><table-wrap position="float" id="pkaf097-T3" orientation="portrait"><label>Table 3.</label><caption><p>Univariate and multivariable analysis for cancer development</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="2" colspan="1">Characteristics</th><th colspan="2" rowspan="1">Univariate analysis<hr/></th><th colspan="2" rowspan="1">Multivariable analysis<hr/></th></tr><tr><th rowspan="1" colspan="1">OR (95% CI)</th><th rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th rowspan="1" colspan="1">OR (95% CI)</th><th rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age, y</td><td rowspan="1" colspan="1">
<bold>1.063 (1.038 to 1.088)</bold>
</td><td rowspan="1" colspan="1">
<bold>&lt;.0001</bold>
</td><td rowspan="1" colspan="1">
<bold>1.062 (1.037 to 1.090)</bold>
</td><td rowspan="1" colspan="1">
<bold>&lt;.0001</bold>
</td></tr><tr><td rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup></td><td rowspan="1" colspan="1">
<bold>1.087 (1.023 to 1.154)</bold>
</td><td rowspan="1" colspan="1">
<bold>.007</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Family history</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>.002</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>.001</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td rowspan="1" colspan="1">Referent</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Referent</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td rowspan="1" colspan="1">
<bold>0.147 (0.043 -to 0.498)</bold>
</td><td rowspan="1" colspan="1">
<bold>.002</bold>
</td><td rowspan="1" colspan="1">
<bold>0.129 (0.037 to 0.451)</bold>
</td><td rowspan="1" colspan="1">
<bold>.0001</bold>
</td></tr><tr><td rowspan="1" colspan="1">Occupation</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>.003</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Employed</td><td rowspan="1" colspan="1">
<bold>4.622 (1.977 to 10.802)</bold>
</td><td rowspan="1" colspan="1">
<bold>&lt;.0001</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Educative profession</td><td rowspan="1" colspan="1">
<bold>3.485 (1.166 to 10.418)</bold>
</td><td rowspan="1" colspan="1">
<bold>.025</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Health-care profession</td><td rowspan="1" colspan="1">
<bold>3.833 (1.447 to 10.157)</bold>
</td><td rowspan="1" colspan="1">
<bold>.007</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Unemployed or retired</td><td rowspan="1" colspan="1">
<bold>7.241 (2.628 to 19.948)</bold>
</td><td rowspan="1" colspan="1">
<bold>&lt;.0001</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Other</td><td rowspan="1" colspan="1">Referent</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Smoking habits</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>.012</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td rowspan="1" colspan="1">Referent</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td rowspan="1" colspan="1">
<bold>1.974 (1.160 to 3.361)</bold>
</td><td rowspan="1" colspan="1">
<bold>.012</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">No. cigarettes per day</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>.016</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>.014</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;Non smoker</td><td rowspan="1" colspan="1">Referent</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Referent</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&lt;10</td><td rowspan="1" colspan="1">1.167 (0.599 to 2.271)</td><td rowspan="1" colspan="1">.650</td><td rowspan="1" colspan="1">1.146 (0.560 to 2.344)</td><td rowspan="1" colspan="1">.709</td></tr><tr><td rowspan="1" colspan="1">&#8195;10-20</td><td rowspan="1" colspan="1">
<bold>3.231 (1.344 to 7.764)</bold>
</td><td rowspan="1" colspan="1">
<bold>.009</bold>
</td><td rowspan="1" colspan="1">
<bold>3.472 (1.386 to 8.699)</bold>
</td><td rowspan="1" colspan="1">
<bold>.008</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;&gt;20</td><td rowspan="1" colspan="1">
<bold>4.846 (1.055 to 22.253)</bold>
</td><td rowspan="1" colspan="1">
<bold>.042</bold>
</td><td rowspan="1" colspan="1">
<bold>5.440 (1.080 to 27.406)</bold>
</td><td rowspan="1" colspan="1">
<bold>.040</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;Pack/years index</td><td rowspan="1" colspan="1">
<bold>1.052 (1.007 to 1.099)</bold>
</td><td rowspan="1" colspan="1">
<bold>.022</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Estroprogestin use (EP)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>.032</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>.025</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td rowspan="1" colspan="1">Referent</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Referent</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td rowspan="1" colspan="1">
<bold>1.829 (1.052 to 3.178)</bold>
</td><td rowspan="1" colspan="1">
<bold>.032</bold>
</td><td rowspan="1" colspan="1">
<bold>2.009 (1.092 to 3.696)</bold>
</td><td rowspan="1" colspan="1">
<bold>.025</bold>
</td></tr><tr><td rowspan="1" colspan="1">Years of estroprogestinic use</td><td rowspan="1" colspan="1">
<bold>1.074 (1.007 to 1.146)</bold>
</td><td rowspan="1" colspan="1">
<bold>.029</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Mediterranean diet</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.203</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.118</td></tr><tr><td rowspan="1" colspan="1">&#8195;Low adherence</td><td rowspan="1" colspan="1">1.477 (0.607 to 3.593)</td><td rowspan="1" colspan="1">.389</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Moderate adherence</td><td rowspan="1" colspan="1">0.718 (0.434 to 1.190)</td><td rowspan="1" colspan="1">.199</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;High adherence</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Physical activity</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.510</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.441</td></tr><tr><td rowspan="1" colspan="1">&#8195;Inactive</td><td rowspan="1" colspan="1">0.757 (0.402 to 1.425)</td><td rowspan="1" colspan="1">.388</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Moderate active</td><td rowspan="1" colspan="1">0.710 (0.392 to 1.285)</td><td rowspan="1" colspan="1">.258</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Active</td><td rowspan="1" colspan="1">Referent</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><p>Abbreviations: CI = confidence interval; OR = odds ratio.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>Breast cancer and ovarian cancer are 2 of the most common cancers in women all over the world. Their occurrence is associated&#160;with different risk factors. The most common causes were age, ethnic group, menarche history, breast gland characteristics, family history, reproductive patterns, pregnancy at a later age, estroprogestinic and alcohol use, smoking habits, diet, and physical activity.<xref rid="pkaf097-B23" ref-type="bibr"><sup>23-25</sup></xref> In some cases, their occurrence is linked to <italic toggle="yes">BRCA</italic> pathogenetic variant genes or other genes that cause a high risk (up to 72% for breast cancer and up to 44% for ovarian cancer).<xref rid="pkaf097-B11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="pkaf097-B26" ref-type="bibr"><sup>26</sup></xref> Increasing evidence supports that genetic predisposition is influenced by environmental factors, likely acting synergistically with genetics to develop cancer.<xref rid="pkaf097-B27" ref-type="bibr"><sup>27</sup></xref></p><p>Interestingly, several environmental factors such as bisphenol A and cadmium as well as other phthalates are well known to play a role in hormonal carcinogenesis.<xref rid="pkaf097-B28" ref-type="bibr"><sup>28-29</sup></xref> In particular, cadmium, released into the soil, water, and air from industrial processing and absorbed into the body from dietary sources, cigarette smoke, and by inhalation in industrial or polluted environments, acts as an activator of cell proliferation.<xref rid="pkaf097-B30" ref-type="bibr"><sup>30-32</sup></xref> In fact, it binds the estrogen receptor in breast cancer cells and promotes cell proliferation through the activation of <italic toggle="yes">PI3K-NRF2</italic>.<xref rid="pkaf097-B13" ref-type="bibr"><sup>13-16</sup></xref> Further, we have recently demonstrated a role of cadmium as well as other environmental pollutants in hormonal carcinogenesis of breast cancer in preclinical experimental models, demonstrating a potential pivotal role of the exposome in cancer development.<xref rid="pkaf097-B30" ref-type="bibr"><sup>30-33</sup></xref></p><p>To our knowledge, few studies have evaluated the influence of environmental factors in population carrier of <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> pathogenetic variant genes. Furthermore, few studies have investigated the role of a harmful lifestyle and obesity in the development of cancer in the same participants. Our purpose was to compare patients with genetic predisposition by dividing them into 2 groups (patients who developed breast cancer and/or ovarian cancer and patients unaffected) evaluating whether and what environmental factors had any influence in the development of cancer.</p><p>We enrolled 281 patients (168 [59.8%] <italic toggle="yes">BRCA1</italic> and 113 [40.2%] <italic toggle="yes">BRCA2</italic> carriers) into a case-control study. There was no statistically significant difference between the 2 groups according to the gene involved, with equal distribution of pathogenetic variant genes in <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic>, respectively, in patients developing cancer and those unaffected at time of observation. Overall, 170 (60.5%) developed breast cancer and/or ovarian cancer and 111 (39.5%) had no diagnosis at the last observation.</p><p>These 2 groups differed regarding age at the time patients had a positive gene test and time of cancer development. Patients with cancer had a higher mean age (44.7 years vs 37.3 years; <italic toggle="yes">P&#8201;</italic>&lt;&#8201;.0001). This difference can be explained because usually the first genetic test (the diagnostic test) is performed in a family when there is evidence of cancer. Subsequently, cascade genetic testing is performed by family members, often younger and healthy,&#160;to verify whether they have inherited the family-specific variant and have proper risk and surveillance advice. Subgroup analysis showed that patients with ovarian cancer have a higher age of onset of neoplasia than patients with breast cancer and without neoplasia (<xref rid="sup1" ref-type="supplementary-material">Table S2</xref>). The difference in age at onset could also explain the difference regarding family history. Patients that are unaffected have a higher incidence of cancer among family members (97.3% vs 84.1%; <italic toggle="yes">P&#8201;</italic>&lt;&#8201;.001) because they were tested especially if a family member had the pathogenetic variant.</p><p>The 2 groups differ also regarding smoking habits, which was higher among ovarian cancer vs breast cancer patients (38.8% vs 24.3%; <italic toggle="yes">P&#8201;</italic>=&#8201;.008). Group 1 showed a higher number of cigarettes smoked (7% vs 1.8% participants with more than 20 cigarettes per day smoked and 16.5% vs 6.3% smoking between 10 and 20 cigarettes per day). This was associated with an higher pack-year index (4.2 vs 2.0; <italic toggle="yes">P&#8201;</italic>=&#8201;.001). Furthermore, we also recorded a statistically significant difference regarding the use of estroprogestin. Patients with cancer used estroprogestin more than unaffected subjects (33.5% vs 21.6%; <italic toggle="yes">P&#8201;</italic>=&#8201;.021) and for a longer time (2.4 vs 1.1&#8201;years; <italic toggle="yes">P&#8201;</italic>&lt;&#8201;.001). However, the use of estroprogestin does not seem to affect patients with ovarian cancer.</p><p>Finally, we found that independent factors for cancer development were BMI (OR = 1.087; <italic toggle="yes">P&#8201;</italic>=&#8201;.007) and occupation (<italic toggle="yes">P&#8201;</italic>=&#8201;.003). However, we did not find a relationship between the development of cancer and both physical activity and Mediterranean diet adherence (group 1 reported poor adherence to the Mediterranean diet compared with group 2, although it did not reach statistical significance [11.8% vs 7.2%; <italic toggle="yes">P&#8201;</italic>=&#8201;.201]). Although BMI emerged as an independent factor for cancer development, it is worth noting that adherence to healthier dietary patterns, such as the Mediterranean diet, has been associated with lower BMI and improved metabolic profiles. Interestingly, a systematic review of the literature and a mini review investigated the role of modifiable factors on malignancy development in women who were <italic toggle="yes">BRCA</italic> mutation carriers, describing few and contradictory results.<xref rid="pkaf097-B33" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="pkaf097-B34" ref-type="bibr"><sup>34</sup></xref> This not statistically significant trend could suggest that preexisting dietary habits, potentially combined with other lifestyle factors, may have contributed to cancer development in susceptible individuals. However, this hypothesis requires confirmation in larger cohorts, as postdiagnosis changes in dietary behavior may also confound these observations.</p><p>In the&#160;multivariable analysis, 4 factors were associated with a predictive role: age, family history, smoking habits, and estroprogestin use. Age was predictive (OR = 1.062; <italic toggle="yes">P&#8201;</italic>&lt;&#8201;.0001) probably because of the longer exposure to environmental or lifestyle factors leading to a higher possibility of developing cancer. The second risk factor was family history, namely whether another first-degree family member had been affected by breast or ovarian cancer, as previously reported in the literature.<xref rid="pkaf097-B35" ref-type="bibr"><sup>35</sup></xref> However, healthy patients usually undergo genetic testing only if at least one family member is positive. In our study, healthier patients have at least 1 family member with cancer (OR = 0.129; <italic toggle="yes">P&#8201;</italic>=&#8201;.001). The third factor was smoking habits; women with smoking habits may have a higher chance of developing cancer. This possibility increases with as the number&#160;of cigarettes smoked increases (<italic toggle="yes">P&#8201;</italic>=&#8201;.014). This evidence could be associated with cadmium exposure, present in inhaled smoke. The greater the number of cigarettes smoked, the greater the inhalation of cadmium and the greater the induced damage to DNA and the risk of developing cancer. We confirmed, even in patients with <italic toggle="yes">BRCA</italic> pathogenetic variant genes, that smoking has a causal role in the development of breast cancer.<xref rid="pkaf097-B36" ref-type="bibr"><sup>36</sup></xref> We also obtained evidence for a potential role of estroprogestin use. The assumptions of estroprogestin use caused an increased risk of developing cancer, especially breast cancer (OR = 2.009; <italic toggle="yes">P&#8201;</italic>=&#8201;.025).<xref rid="pkaf097-B37" ref-type="bibr"><sup>37</sup></xref> One possible explanation for this finding is the presence of a high number of hormones that stimulate the proliferation of glandular cells, which in the presence of an altered DNA repair mechanism could promote the development of cancer. However, the use of estroprogestin does not seem to affect ovarian cancer development. Some studies report data on a protective role of estroprogestins on the occurrence of ovarian cancer.<xref rid="pkaf097-B38" ref-type="bibr"><sup>38</sup></xref></p><p>Our study is primarily limited by its retrospective design. The information was obtained before diagnosis of cancer and at enrollment for healthy patients, therefore, changes in lifestyle after treatment could have altered the results. After diagnosis, patients might have changed their lifestyle with the introduction of healthy modifications and, thus, potential alteration of responses to the questionnaire. Another weakness was the lack of data on serum cadmium levels, which could have further helped the potential direct role of this environmental contaminant as a risk factor in malignancy development.</p><p>One strength is that the inclusion of women with and without cancer enhances the robustness of the study design by allowing a direct comparison between groups, thereby improving the identification of environmental and lifestyle factors that may influence cancer development in <italic toggle="yes">BRCA</italic> pathogenetic variant gene carriers. Additionally, the inclusion of validated tools (17-item PREDIMED questionnaire for dietary adherence and IPAQ-SF for physical activity) ensures the reliability and reproducibility of the collected data. The study captures demographic, lifestyle, and clinical information, facilitating a thorough analysis of factors influencing cancer risk. Finally, we used a multidisciplinary approach. Integrating genetic, environmental, and lifestyle factors, the study adopts a holistic and multidisciplinary approach that is essential for understanding the complex interplay between genetic predisposition and environmental influences. A prospective study is also warranted to capture further information in an era of greater awareness of the population&#8217;s lifestyles.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>pkaf097_Supplementary_Data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pkaf097_supplementary_data.zip" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><title>Acknowledgments</title><p>This paper is dedicated to the memory of our dear colleague Prof. Giovanni Scambia who passed away while this work was being finalized.</p><p>The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; or the writing of the manuscript and decision to submit it for publication.</p></ack><sec><title>Author contributions</title><p>Alessandra Fabi (Conceptualization, Supervision, Writing&#8212;review &amp; editing), Antonio Franco (Conceptualization, Data curation, Formal analysis, Writing&#8212;original draft), Laura Cortesi (Conceptualization, Writing&#8212;review &amp; editing), Emanuela Lucci Cordisco (Conceptualization, Data curation, Writing&#8212;original draft), Alessandro Rossi (Data curation, Formal analysis, Writing&#8212;original draft), Daniela Andreina Terribile (Data curation, Writing&#8212;original draft), Elena Fiorio (Conceptualization, Investigation), Ida Paris (Conceptualization, Writing&#8212;original draft), Giovanni Terrana (Data curation), Edoardo Mocini (Data curation, Investigation), Vanda Salutari (Investigation, Writing&#8212;original draft), Francesco Pavese (Conceptualization, Data curation, Investigation), Federica Francesca L&#8217;Erario (Data curation, Investigation), Domizia Pasquetti (Data curation, Investigation), Antonella Palazzo (Conceptualization, Data curation, Investigation), Enrico Di Guglielmo (Data curation, Investigation, Writing&#8212;original draft), Alejandro Martin Sanchez (Data curation, Investigation, Writing&#8212;original draft), Sabatino D&#8217;Archi (Data curation, Investigation, Writing&#8212;original draft), Elena Giontella (Data curation, Investigation), Alba Di Leone (Investigation, Writing&#8212;original draft), Ludovica Cardinali (Conceptualization, Methodology), Rosa Saltarelli (Data curation, Investigation), Lorenzo Scardina (Data curation, Investigation), Elisabetta Ferretti (Conceptualization, Writing&#8212;original draft), Luisa Carbognin (Writing&#8212;original draft), Michele Milella (Supervision, Writing&#8212;review &amp; editing), Carlo Baldari (Data curation, Investigation), Roberto Bei (Data curation, Investigation), Antonella Carcagni (Data curation, Formal analysis), Giorgia Garganese (Conceptualization, Supervision), Gianluca Franceschini (Supervision, Writing&#8212;review &amp; editing), Maurizio Genuardi (Supervision, Writing&#8212;review &amp; editing), Diana Giannarelli (Data curation, Formal analysis, Supervision, Writing&#8212;review &amp; editing), and Silvia Migliaccio (Conceptualization, Supervision, Writing&#8212;review &amp; editing)</p></sec><sec><title>Supplementary material</title><p>
<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> is available at <italic toggle="yes">JNCI Cancer Spectrum</italic> online.</p></sec><sec><title>Funding</title><p>AR was in part supported by a fellowship from the Italian Ministry of Research (grant number PON ARS01 00693) to SM. Research was also supported by co-funding by the European Union-NRRP&#8211;Mission 4 Component 2 Investment 1.3-NextGenerationEU Project PE 00000003-ON Foods-Research and innovation network on food and nutrition Sustainability, Safety and Security-Working ON Food&#8211;CUP D93C22000890001-RTDA: EM. This study was funded by the Italian Minister of Health&#8212;Ricerca Corrente 2023.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p>Fabi Alessandra: Consultant or advisor: Roche, Lilly, Novartis, AstraZeneca, Pfizer, Seagen, Gilead, MSD, Menarini Stemline, and Domp&#232; Biotech; speaker honoraria: AstraZeneca, Roche, Lilly, Novartis, Gilead, Pfizer, and Daiichi Sankyo Exact Sciences; research support: AstraZeneca and Roche.</p><p>Paris Ida: Advisor and speaker honoraria for Novartis, Pfizer, AstraZeneca, Seagen, MSD, Lilly, Gilead, Menarini Stemline, Gentili, Daiichi Sankyo, Genetic, and Iltalfarmaco.</p><p>Palazzo Antonella: Advisory board and speaker honoraria for&#160;AstraZeneca/Daichi Sankyo, Novartis, Pfizer, Exact Sciences, Lilly, Ipsen, and MSD.</p></sec><sec sec-type="data-availability"><title>Data availability</title><p>The data underlying this article are available in the article and in its <xref rid="sup1" ref-type="supplementary-material">online supplementary material</xref>.</p></sec><ref-list id="ref1"><title>References</title><ref id="pkaf097-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></string-name></person-group> &#160;<article-title>Cancer statistics</article-title>. <source>CA Cancer J Clin</source>. <year>2020</year>;<volume>70</volume>:<fpage>7</fpage>-<lpage>30</lpage>.<pub-id pub-id-type="pmid">31912902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21590</pub-id></mixed-citation></ref><ref id="pkaf097-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Harvie</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Howell</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>DG.</given-names></string-name></person-group> &#160;<article-title>Can diet and lifestyle prevent breast cancer: what is the evidence?</article-title> &#160;<source>Am Soc Clin Oncol Educ Book</source>. <year>2015</year>;<fpage>e66-73</fpage>.<pub-id pub-id-type="pmid">25993238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14694/EdBook_AM.2015.35.e66</pub-id></mixed-citation></ref><ref id="pkaf097-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Webb</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Jordan</surname><given-names>SJ.</given-names></string-name></person-group> &#160;<article-title>Epidemiology of epithelial ovarian cancer</article-title>. <source>Best Pract Res Clin Obstet Gynaecol</source>. <year>2017</year>;<volume>41</volume>:<fpage>3</fpage>-<lpage>14</lpage>.<pub-id pub-id-type="pmid">27743768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpobgyn.2016.08.006</pub-id></mixed-citation></ref><ref id="pkaf097-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Renehan</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Tyson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Egger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Heller</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Zwahlen</surname><given-names>M.</given-names></string-name></person-group> &#160;<article-title>Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>371</volume>:<fpage>569</fpage>-<lpage>578</lpage>.<pub-id pub-id-type="pmid">18280327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(08)60269-X</pub-id></mixed-citation></ref><ref id="pkaf097-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pischon</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>N&#246;thlings</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Boeing</surname><given-names>H.</given-names></string-name></person-group> &#160;<article-title>Obesity and cancer</article-title>. <source>Proc Nutr Soc</source>. <year>2008</year>;<volume>67</volume>:<fpage>128</fpage>-<lpage>145</lpage>.<pub-id pub-id-type="pmid">18412987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0029665108006976</pub-id></mixed-citation></ref><ref id="pkaf097-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sebastiani</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cortesi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sant</surname><given-names>M</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Increased incidence of breast cancer in postmenopausal women with high body mass index at the Modena screening program</article-title>. <source>J Breast Cancer</source>. <year>2016</year>;<volume>19</volume>:<fpage>283</fpage>-<lpage>291</lpage>.<pub-id pub-id-type="pmid">27721878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4048/jbc.2016.19.3.283</pub-id><pub-id pub-id-type="pmcid">PMC5053313</pub-id></mixed-citation></ref><ref id="pkaf097-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Piombino</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cortesi</surname><given-names>L.</given-names></string-name></person-group> &#160;<article-title>Insights into the possible molecular mechanisms of resistance to PARP inhibitors</article-title>. <source>Cancers (Basel)</source>. <year>2022</year>;<volume>14</volume>:<fpage>2804</fpage>.<pub-id pub-id-type="pmid">35681784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14112804</pub-id><pub-id pub-id-type="pmcid">PMC9179506</pub-id></mixed-citation></ref><ref id="pkaf097-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brohet</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Velthuizen</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Hogervorst</surname><given-names>FB</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations</article-title>. <source>J Med Genet</source>. <year>2014</year>;<volume>51</volume>:<fpage>98</fpage>-<lpage>107</lpage>.<pub-id pub-id-type="pmid">24285858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmedgenet-2013-101974</pub-id></mixed-citation></ref><ref id="pkaf097-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kuchenbaecker</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>McGuffog</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Barrowdale</surname><given-names>D</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers</article-title>. <source>J Natl Cancer Inst</source>. <year>2017</year>;<volume>109</volume>:<fpage>djw302</fpage>.<pub-id pub-id-type="pmid">28376175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djw302</pub-id><pub-id pub-id-type="pmcid">PMC5408990</pub-id></mixed-citation></ref><ref id="pkaf097-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Paul</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Paul</surname><given-names>S.</given-names></string-name></person-group> &#160;<article-title>The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers</article-title>. <source>Front Biosci (Landmark Ed)</source>. <year>2014</year>;<volume>19</volume>:<fpage>605</fpage>-<lpage>618</lpage>.<pub-id pub-id-type="pmid">24389207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2741/4230</pub-id><pub-id pub-id-type="pmcid">PMC4307936</pub-id></mixed-citation></ref><ref id="pkaf097-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coignard</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lush</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Beesley</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>:<fpage>1078</fpage>.<pub-id pub-id-type="pmid">33597508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-20496-3</pub-id><pub-id pub-id-type="pmcid">PMC7890067</pub-id></mixed-citation></ref><ref id="pkaf097-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kuchenbaecker</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>Hopper</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname><given-names>DR</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers</article-title>. <source>JAMA</source>. <year>2017</year>;<volume>317</volume>:<fpage>2402</fpage>-<lpage>2416</lpage>.<pub-id pub-id-type="pmid">28632866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2017.7112</pub-id></mixed-citation></ref><ref id="pkaf097-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brama</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gnessi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Basciani</surname><given-names>S</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism</article-title>. <source>Mol Cell Endocrinol</source>. <year>2007</year>;<volume>264</volume>:<fpage>102</fpage>-<lpage>108</lpage>.<pub-id pub-id-type="pmid">17125913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mce.2006.10.013</pub-id></mixed-citation></ref><ref id="pkaf097-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fatima</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Raza</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Hadi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Nigam</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mahdi</surname><given-names>AA.</given-names></string-name></person-group> &#160;<article-title>Cadmium in human diseases: it&#8217;s more than just a mere metal</article-title>. <source>Indian J Clin Biochem</source>. <year>2019</year>;<volume>34</volume>:<fpage>371</fpage>-<lpage>378</lpage>.<pub-id pub-id-type="pmid">31686724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12291-019-00839-8</pub-id><pub-id pub-id-type="pmcid">PMC6801231</pub-id></mixed-citation></ref><ref id="pkaf097-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Primas</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kroiss</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kalteis</surname><given-names>K</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers</article-title>. <source>Eur J Cancer Prev</source>. <year>2012</year>;<volume>21</volume>:<fpage>199</fpage>-<lpage>204</lpage>.<pub-id pub-id-type="pmid">22252303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CEJ.0b013e32834c9b22</pub-id></mixed-citation></ref><ref id="pkaf097-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bimonte</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barbieri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Palma</surname><given-names>G</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Dissecting the role of curcumin in tumour growth and angiogenesis in mouse model of human breast cancer</article-title>. <source>Biomed Res Int</source>. <year>2015</year>;<volume>2015</volume>:<fpage>878134</fpage>.<pub-id pub-id-type="pmid">25879038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/878134</pub-id><pub-id pub-id-type="pmcid">PMC4386568</pub-id></mixed-citation></ref><ref id="pkaf097-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pettapiece-Phillips</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Narod</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Kotsopoulos</surname><given-names>J.</given-names></string-name></person-group> &#160;<article-title>The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers</article-title>. <source>Cancer Causes Control</source>. <year>2015</year>;<volume>26</volume>:<fpage>333</fpage>-<lpage>344</lpage>.<pub-id pub-id-type="pmid">25579073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10552-014-0521-0</pub-id></mixed-citation></ref><ref id="pkaf097-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bruno</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Oliverio</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Paradiso</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Lifestyle characteristics in women carriers of BRCA mutations: results from an Italian trial cohort</article-title>. <source>Clin Breast Cancer</source>. <year>2021</year>;<volume>21</volume>:<fpage>e168</fpage>-<lpage>e176</lpage>.<pub-id pub-id-type="pmid">33357965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clbc.2020.11.002</pub-id></mixed-citation></ref><ref id="pkaf097-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grill</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yahiaoui-Doktor</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dukatz</surname><given-names>R</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis</article-title>. <source>Arch Gynecol Obstet</source>. <year>2017</year>;<volume>296</volume>:<fpage>1135</fpage>-<lpage>1144</lpage>.<pub-id pub-id-type="pmid">28975393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00404-017-4546-y</pub-id></mixed-citation></ref><ref id="pkaf097-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Richards</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Aziz</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bale</surname><given-names>S</given-names></string-name></person-group>, <etal>et al</etal>; <collab>Laboratory Quality Assurance Committee</collab>. <article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>. <source>Genet Med</source>. <year>2015</year>;<volume>17</volume>:<fpage>405</fpage>-<lpage>424</lpage>.<pub-id pub-id-type="pmid">25741868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2015.30</pub-id><pub-id pub-id-type="pmcid">PMC4544753</pub-id></mixed-citation></ref><ref id="pkaf097-B21"><label>21</label><mixed-citation publication-type="other"><collab>Endocrine Disruptors and Life STILe in Breast Cancer Development (STILVARCA)</collab>. [Online] <year>2023</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://classic.clinicaltrials.gov/ct2/show/NCT05748353" ext-link-type="uri">https://classic.clinicaltrials.gov/ct2/show/NCT05748353</ext-link></mixed-citation></ref><ref id="pkaf097-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bouzas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bibiloni</surname><given-names>MDM</given-names></string-name>, <string-name name-style="western"><surname>Julibert</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Adherence to the Mediterranean lifestyle and desired body weight loss in a Mediterranean adult population with overweight: a PREDIMED-plus study</article-title>. <source>Nutrients</source>. <year>2020</year>;<volume>12</volume>:<fpage>2114</fpage>.<pub-id pub-id-type="pmid">32708828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu12072114</pub-id><pub-id pub-id-type="pmcid">PMC7400596</pub-id></mixed-citation></ref><ref id="pkaf097-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Winters</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shokar</surname><given-names>NK.</given-names></string-name></person-group> &#160;<article-title>Breast cancer epidemiology, prevention, and screening</article-title>. <source>Prog Mol Biol Transl Sci</source>. <year>2017</year>;<volume>151</volume>:<fpage>1</fpage>-<lpage>32</lpage>.<pub-id pub-id-type="pmid">29096890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.pmbts.2017.07.002</pub-id></mixed-citation></ref><ref id="pkaf097-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yoneda</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lendorf</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Couchman</surname><suffix>Jr.</suffix></string-name>, <string-name name-style="western"><surname>Multhaupt</surname><given-names>HA.</given-names></string-name></person-group> &#160;<article-title>Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans</article-title>. <source>J Histochem Cytochem</source>. <year>2012</year>;<volume>60</volume>:<fpage>9</fpage>-<lpage>21</lpage>.<pub-id pub-id-type="pmid">22205677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1369/0022155411428469</pub-id><pub-id pub-id-type="pmcid">PMC3283135</pub-id></mixed-citation></ref><ref id="pkaf097-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brekelmans</surname><given-names>CT.</given-names></string-name></person-group> &#160;<article-title>Risk factors and risk reduction of breast and ovarian cancer</article-title>. <source>Curr Opin Obstet Gynecol</source>. <year>2003</year>;<volume>15</volume>:<fpage>63</fpage>-<lpage>68</lpage>.<pub-id pub-id-type="pmid">12544504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00001703-200302000-00010</pub-id></mixed-citation></ref><ref id="pkaf097-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Engel</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname><given-names>C.</given-names></string-name></person-group> &#160;<article-title>Breast cancer risks and risk prediction models</article-title>. <source>Breast Care (Basel)</source>. <year>2015</year>;<volume>10</volume>:<fpage>7</fpage>-<lpage>12</lpage>.<pub-id pub-id-type="pmid">25960719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000376600</pub-id><pub-id pub-id-type="pmcid">PMC4395818</pub-id></mixed-citation></ref><ref id="pkaf097-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coletta</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Gatus</surname><given-names>LA</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Diet, weight management, physical activity and ovarian &amp; breast cancer risk in women with BRCA1/2 pathogenic germline gene variants: systematic review</article-title>. <source>Hered Cancer Clin Pract</source>. <year>2020</year>;<volume>18</volume>:<fpage>5</fpage>.<pub-id pub-id-type="pmid">32165993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13053-020-0137-1</pub-id><pub-id pub-id-type="pmcid">PMC7060535</pub-id></mixed-citation></ref><ref id="pkaf097-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J.</given-names></string-name></person-group> &#160;<article-title>Phthalates unleashed: decoding ovarian carcinogenesis through multi-omics networks, single-cell insights, and molecular docking</article-title>. <source>J Ovarian Res</source>. <year>2025</year>; <volume>18</volume>:<fpage>131</fpage>.<pub-id pub-id-type="pmid">40517225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13048-025-01710-6</pub-id><pub-id pub-id-type="pmcid">PMC12166584</pub-id></mixed-citation></ref><ref id="pkaf097-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Singh</surname><given-names>DD.</given-names></string-name></person-group> &#160;<article-title>Epigenetic mechanisms of endocrine-disrupting chemicals in breast cancer and their impact on dietary intake</article-title>. <source>J Xenobiot</source>. <year>2024</year>;<volume>15</volume>:<fpage>1</fpage>.<pub-id pub-id-type="pmid">39846533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jox15010001</pub-id><pub-id pub-id-type="pmcid">PMC11755457</pub-id></mixed-citation></ref><ref id="pkaf097-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Citarella</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Besharat</surname><given-names>ZM</given-names></string-name>, <string-name name-style="western"><surname>Coppola</surname><given-names>L</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Bisphenol A drives nuclear factor-kappa B signaling activation and enhanced motility in non-transformed breast cells</article-title>. <source>Environ Pollut</source>. <year>2025</year>;<volume>376</volume>:<fpage>126422</fpage>.<pub-id pub-id-type="pmid">40360080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.envpol.2025.126422</pub-id></mixed-citation></ref><ref id="pkaf097-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Focaccetti</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Nardozi</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Benvenuto</surname><given-names>M</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Bisphenol-A in drinking water accelerates mammary cancerogenesis and favors an immunosuppressive tumor microenvironment in BALB-neuT mice</article-title>. <source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>:<fpage>6259</fpage>.<pub-id pub-id-type="pmid">38892447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25116259</pub-id><pub-id pub-id-type="pmcid">PMC11172679</pub-id></mixed-citation></ref><ref id="pkaf097-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bimonte</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Catanzaro</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Po</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>The endocrine disruptor cadmium modulates the androgen-estrogen receptors ratio and induces inflammatory cytokines in luminal (A) cell models of breast cancer</article-title>. <source>Endocrine</source>. <year>2024</year>;<volume>83</volume>:<fpage>798</fpage>-<lpage>809</lpage>.<pub-id pub-id-type="pmid">37979099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12020-023-03594-2</pub-id><pub-id pub-id-type="pmcid">PMC10902028</pub-id></mixed-citation></ref><ref id="pkaf097-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Daniele</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Divella</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pilato</surname><given-names>B</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Can harmful lifestyle, obesity and weight changes increase the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers? A Mini review</article-title>. <source>Hered Cancer Clin Pract</source>. <year>2021</year>;<volume>19</volume>:<fpage>45</fpage>.<pub-id pub-id-type="pmid">34706754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13053-021-00199-6</pub-id><pub-id pub-id-type="pmcid">PMC8554866</pub-id></mixed-citation></ref><ref id="pkaf097-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cohen</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Stoll</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Anandarajah</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Doering</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Colditz</surname><given-names>GA.</given-names></string-name></person-group> &#160;<article-title>Modifiable risk factors in women at high risk of breast cancer: a systematic review</article-title>. <source>Breast Cancer Res</source>. <year>2023</year>;<volume>25</volume>:<fpage>45</fpage>.<pub-id pub-id-type="pmid">37095519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13058-023-01636-1</pub-id><pub-id pub-id-type="pmcid">PMC10123992</pub-id></mixed-citation></ref><ref id="pkaf097-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bellcross</surname><given-names>CA.</given-names></string-name></person-group> &#160;<article-title>Hereditary breast and ovarian cancer: an updated primer for OB/GYNs</article-title>. <source>Obstet Gynecol Clin North Am</source>. <year>2022</year>;<volume>49</volume>:<fpage>117</fpage>-<lpage>147</lpage>.<pub-id pub-id-type="pmid">35168766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ogc.2021.11.005</pub-id></mixed-citation></ref><ref id="pkaf097-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scala</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bosetti</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bagnardi</surname><given-names>V</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Dose-response relationships between cigarette smoking and breast cancer risk: a systematic review and meta-analysis</article-title>. <source>J Epidemiol</source>. <year>2023</year>;<volume>33</volume>:<fpage>640</fpage>-<lpage>648</lpage>.<pub-id pub-id-type="pmid">36967121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2188/jea.JE20220206</pub-id><pub-id pub-id-type="pmcid">PMC10635814</pub-id></mixed-citation></ref><ref id="pkaf097-B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iodice</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barile</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rotmensz</surname><given-names>N</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis</article-title>. <source>Eur J Cancer</source>. <year>2010</year>;<volume>46</volume>:<fpage>2275</fpage>-<lpage>2284</lpage>.<pub-id pub-id-type="pmid">20537530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2010.04.018</pub-id></mixed-citation></ref><ref id="pkaf097-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pragout</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Laurence</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Baffet</surname><given-names>H</given-names></string-name></person-group>, <etal>et al</etal> &#160;<article-title>Contraception et cancer. RPC contraception CNGOF [Contraception and cancer: CNGOF contraception guidelines]</article-title>. <source>Gynecol Obstet Fertil Senol</source>. <year>2018</year>;<volume>46</volume>:<fpage>834</fpage>-<lpage>844</lpage>.<pub-id pub-id-type="pmid">30385358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gofs.2018.10.010</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>